A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

201831 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov identifier: NCT02287779 (registration first received 6 November 2014).

Good health and well-being

Published in: BMC Pharmacology and Toxicology

Volume 19, Issue 1, pp. 10-10

Field-Weighted Citation Impact: 3.08